Future Medicine Ltd has announced the launch of a new journal, Hepatic Oncology. This new title focuses specifically on the specialism of hepatic cancer, including both primary and secondary malignancies.
An important opportunity has opened up for interventional oncologists as WCIO leaders take the helm of the E1208 trial. Michael C Soulen writes that the change in the trial leadership from medical oncology to interventional oncology represents a challenge because it rests on the question: can interventional oncologists run a successful cooperative group trial of image-guided therapy?
Guerbet has announced that it has been granted Orphan Drug Designation from the US Food and Drug Administration Office of Orphan Products Development (OOPD) for Lipiodol (ethiodised oil) injection for management of patients with known hepatocellular carcinoma.
The NHS revision of Clinical Policy Commissioning Statement on SIRT will allow patients in England with metastatic colorectal cancer and intrahepatic cholangiocarcinoma who may benefit from the therapy to get treatment in specialist NHS centres.
Angiovac cannula and cardiopulmonary bypass circuit, Bioflo peripherally inserted central catheters, Nanoknife system, Nevertouch direct fibre and Acculis microwave system illustrate strength of company’s portfolio.
Thomas Vogl, Institute of Diagnostic and Interventional Radiology, Goethe University, Frankfurt, spoke at ECIO (19–22 June, Budapest Hungary) about novel lung ablative techniques and the evidence for combination ablative therapies.
The presentation will include the most recent overall survival data. Recent HEAT study post-hoc analysis, strongly suggest positive progression-free survival and overall survival in ThermoDox treated patients when heating cycles from the radiofrequency ablation procedure were optimised.
For the two-thirds of lung cancer patients with locally advanced or metastatic disease, tumour size is not used currently to predict overall survival times. A new study, however, led by UT Southwestern Medical Center researchers has shown that even in advanced stages, total tumour size can have a major impact on survival.
Results of an analysis by members of the multicentre European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY), published online in late May in the Journal of Hepatology, may have important implications for older patients with inoperable primary liver cancer.
BTG announced on 30 July that the National Institute for Health and Clinical Excellence (NICE) has issued guidance recommending the use of selective internal radiation therapy (SIRT), which includes TheraSphere, for patients with liver cancer across the NHS.
Sirtex Medical and US-based Surefire Medical has announced a sales and marketing partnership to distribute Surefire’s range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.
Launched by the Assistance Publique Hôpitaux de Paris, France, in December 2011, SARAH (Sorafenib versus radioembolization in advanced hepatocellular carcinoma), a French national collaborative randomised controlled trial of radioembolization with yttrium-90 resin microspheres vs. sorafenib in advanced hepatocellular carcinoma has announced it is seeking to enrol 400 patients.
Cancer experts have reported future trends and progress in radiotherapy treatments for lung cancer using motion management and tumour-tracking technologies from Varian Medical Systems at the annual ESTRO Forum (19–23 April 2013, Geneva, Switzerland).
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery according to study findings conducted by Panaxea, The University of Twente, The Netherlands.
Elekta recently received 510(k) clearance from the US Food and Drug Administration (FDA) which allows the company to begin shipping and installation of all components of the Versa HD system within the USA.
On 11–12 April, Nordion will host its 3rd European TheraSphere User Group Meeting in Vienna, Austria, and on 18 April, Nordion will offer a Satellite Symposium at the 3rd Interdisciplinary Treatment of Liver Tumors (ITLT) Meeting in Essen, Germany, according to a company release.
Two-year data from a prospective, multicentre study suggest that endovascular therapy with stenting may be considered the preferred first-line treatment option for aortoiliac lesions, irrespectively ...